Apranax Forte: instructions for use

  • October 6, 2018
  • Rheumatology
  • Catherine

Apranax Forte is a drug that is widely used in medicine to treat various musculoskeletal pathologies. You should take the medicine only as prescribed by your doctor. Before use, you must read the instructions for use of Apranax Forte.

pharmachologic effect

The oral drug has antipyretic, analgesic and anti-inflammatory properties. The mechanism of action is explained by inhibition of the migration of leukocytes, mediators of inflammatory processes and lysosomes. Under the influence of naproxen, PG synthesis is inhibited.

According to the instructions for Apranax Forte, the active substance is absorbed in the gastrointestinal tract immediately after the tablet is taken orally. The maximum content of the substance in the blood plasma is achieved after 2-4 hours.

Indications for use

Due to these characteristics, tablets are prescribed for the following pathologies:

  • Degenerative diseases or rheumatic inflammation of acute and chronic course (this list includes arthrosis, rheumatoid arthritis, ankylosing spondylitis).
  • Gout.
  • Traumatic stroke.
  • Recovery period after surgical interventions.
  • Extra-articular rheumatism (this can be lumbago, tendonitis, bursitis;
  • Dysmenorrhea.

Synonyms of nosological groups

Category ICD-10Synonyms of diseases according to ICD-10
M05 Seropositive rheumatoid arthritisRheumatoid arthritis seropositive
M10 GoutExacerbation of gout
Acute joint attack due to gout
Acute gouty attack
Gout attack
Recurrent attacks of gout
Chronic gout
M45 Ankylosing spondylitisAnkylosing spondylitis
Ankylosing spondylitis
Ankylosing spondylitis
Pain syndrome in acute inflammatory diseases of the musculoskeletal system
Pain syndrome in chronic inflammatory diseases of the musculoskeletal system
Diseases of the spinal column
Ankylosing spondylitis
Ankylosing spondylitis-Marie-Strumpell disease
Marie-Strumpel's disease
Rheumatic spondylitis
Ankylosing spondyloarthritis
M71 Other bursopathiesBursitis
Bursopathy
Inflammatory soft tissue disease
Soft tissue diseases
Edema syndrome in muscular-articular diseases
Subacute bursitis
M77.9 Enthesopathy, unspecifiedCapsulitis
Periarthritis
Periarthropathy
Tendinitis
Tendopathy
M79.0 Rheumatism, unspecifiedDegenerative rheumatic disease
Degenerative and rheumatic tendon diseases
Degenerative rheumatic diseases
Localized forms of soft tissue rheumatism
Rheumatism
Rheumatism with a pronounced allergic component
Rheumatism articular and extra-articular
Rheumatic attack
Rheumatic complaints
Rheumatic diseases
Rheumatic diseases of the intervertebral disc
Rheumatic disease
Rheumatic spine disease
Rheumatoid diseases
Relapses of rheumatism
Articular and extra-articular rheumatism
Articular and muscular rheumatism
Articular rheumatism
Articular syndrome in rheumatism
Chronic rheumatic pain
Chronic articular rheumatism
N94.6 Dysmenorrhea, unspecifiedAlgomenorrhea
Algomenorrhea
Pain syndrome due to smooth muscle spasms
Pain syndrome due to smooth muscle spasms (renal and biliary colic, intestinal spasms, dysmenorrhea)
Pain syndrome due to spasms of smooth muscles of internal organs
Pain syndrome due to spasms of smooth muscles of internal organs (renal and biliary colic, intestinal spasms, dysmenorrhea)
Pain during menstruation
Painful, irregular periods
Pain during menstruation
Pain during menstruation
Dysalgomenorrhea
Dysmenorrhea
Dysmenorrhea (essential) (exfoliative)
Menstrual disorder
Menstrual crumpies
Menstruation is painful
Metrorrhagia
Menstrual irregularities
Menstrual irregularities
Primary dysalgomenorrhea
Prolactin-dependent menstrual disorder
Prolactin-dependent menstrual dysfunction
Menstrual disorder
Spasmodic dysmenorrhea
Functional disorders of the menstrual cycle
Functional disorders of the menstrual cycle
R52.2 Other persistent painPain syndrome of non-rheumatic origin
Pain syndrome with vertebrogenic lesions
Pain syndrome with neuralgia
Pain syndrome from burns
Pain syndrome is mild or moderate
Neuropathic pain
Neuropathic pain
Perioperative pain
Moderate to severe pain
Moderate or mild pain syndrome
Moderate to severe pain syndrome
Ear pain due to otitis media

Dosage and regimen for adults

The medicine is intended for oral administration. In this case, the tablet is swallowed whole and washed down with plenty of water. Chewing or crushing the tablets is not recommended. The doctor prescribes the dosage and number of doses based on the patient’s diagnosis and the severity of the disease.

At the beginning of therapy or during periods of exacerbation of symptoms, 1100 mg of the drug per day is often used. This dose is taken in the morning or divided into 2 doses (morning and evening). The interval between doses should be 12 hours. After the patient's condition improves, the dosage is reduced according to the instructions. Reviews of Apranax Forte confirm the high effectiveness of the drug. Already after 2-3 days there is a noticeable weakening of symptoms.

For the treatment of dysmenorrhea, 550 mg of naproxen is prescribed in the first days. Then the dosage is reduced to 275 mg at intervals of 6-8 hours.

For gout, the initial dosage is 825 mg, then it is reduced to 275 mg. Take tablets at intervals of 8 hours.

The instructions for use of Apranax Forte read as follows: the maximum daily dose for an adult is 1375 mg of naproxen.

Notes

  1. . medscape.com
    . WebMD LLC. Retrieved May 17, 2021.
  2. Simon Law;
    Sheena Derry; R Andrew Moore. .
    Naproxen alone or in combination with an antiemetic for acute migraine headaches in adults
    .
  3. Simon Law;
    Sheena Derry; R Andrew Moore. .
    A single oral dose of naproxen or naproxen sodium for acute postoperative pain in adults
    .
  4. . drugs.com
    . Drugs.com. Retrieved May 17, 2021.
  5. . TOXNET
    . NIH. Retrieved July 21, 2021.
  6. . Clinical Correlations
    . New York University. Retrieved May 4, 2021.
  7. . PubMed Health
    (September 1, 2008).
  8. Australian Medicines Handbook. - 2013. - The Australian Medicines Handbook Unit Trust, 2013. - ISBN 978-0-9805790-9-3.
  9. Joint Formulary Committee.
    British National Formulary (BNF). - 65. - London, UK: Pharmaceutical Press, 2013. - P. 665, 673. - ISBN 978-0-85711-084-8.
  10. . FDA
    (July 9, 2015). Retrieved February 1, 2021.
  11. McIlwraith CW, Frisbie DD, Kawcak CE. Nonsteroidal Anti-Inflammatory Drugs. Proc. AAEP 2001 (47): 182-187.
  12. May SA, Lees P. Nonsteroidal anti-inflammatory drugs. In McIlwraith CW, Trotter GW, eds. Joint disease in the horse. Philadelphia: WB Saunders, 1996;223–237.

Pediatric dosage

The drug can be used in pediatrics, but it is prescribed with extreme caution. Treatment is carried out under the supervision of a doctor.

For children over 1 year of age, no more than 11 mg/kg body weight is recommended for the treatment of rheumatoid arthritis. This daily dose is divided into 2 doses (morning and evening) with an interval of 12 hours.

These tablets are not prescribed to children under 1 year of age.

Apranax oral tablets

Instructions for medical use of the drug

Description of pharmacological action

Naproxen inhibits PG synthesis.

Indications for use

Acute and chronic pain in rheumatic inflammatory and degenerative diseases (rheumatoid arthritis, arthrosis, ankylosing spondylitis), extra-articular rheumatism (bursitis, tendonitis, lumbago, etc.), dysmenorrhea, surgical interventions and traumatic stroke, gout.

Release form

tablets 550 mg; blister 10, box (box) 1; tablets 550 mg; blister 10, box (box) 5;

Pharmacodynamics

NSAIDs have anti-inflammatory, analgesic and antipyretic effects associated with non-selective suppression of the activity of COX1 and COX2, which regulate the synthesis of Pg.

Use during pregnancy

Use of naproxen during late pregnancy may result in delayed labor, persistent pulmonary hypertension, renal dysfunction, and abnormal prostaglandin E levels in premature infants. Since the effects of substances of this class on the cardiovascular system of the fetus are known (closure of the ductus bollus), use in the third trimester is excluded. FDA Category of Effect on the Fetus is C. Naproxen is detected in breast milk in women (concentration is approximately 1% serum). Because there may be adverse effects of substances that inhibit PG synthesis in neonates, naproxen should not be used by nursing mothers.

Contraindications for use

Hypersensitivity, allergy to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs, gastric and duodenal ulcers in the acute phase, pregnancy (especially in the third trimester), lactation, age (up to 1 year).

Side effects

Gastrointestinal disorders (nausea, vomiting, epigastric discomfort, feeling of fullness in the stomach, diarrhea), headache, dizziness, decreased attention, impaired thinking, insomnia, tinnitus, hearing loss, erosive and ulcerative lesions (including ulcerative stomatitis ), bleeding and perforation of the gastrointestinal tract, colitis, jaundice, hepatitis, eosinophilic pneumonia, nephropathy, hematuria, thrombocytopenia, granulocytopenia, aplastic and hemolytic anemia, exudative erythema multiforme, vasculitis, porphyrodermatosis, alopecia, photosensitivity, epidermal necrolysis, anaphylactoid and skin reactions, angioedema edema.

Directions for use and doses

Orally, without chewing, with a small amount of liquid. At the beginning of treatment and during exacerbation, 1100 mg/day (maximum - 1375 mg) is prescribed in 1 (in the evening) or 2 doses (with an interval of 12 hours). For dysmenorrhea, the initial dose is 550 mg, then 275 mg every 6-8 hours for 3-4 days; for gout, the initial dose is 825 mg, then 275 mg every 8 hours (until the attack ends). For children over 1 year old with juvenile rheumatoid arthritis - 11 mg/kg/day is prescribed in 2 doses (with an interval of 12 hours).

Overdose

Symptoms: drowsiness, lethargy, dizziness, epigastric pain, abdominal discomfort, heartburn, dyspepsia, nausea, transient liver dysfunction, hypoprothrombinemia, renal dysfunction, metabolic acidosis, apnea, disorientation, vomiting; possible bleeding from the gastrointestinal tract; rarely - hypertension, acute renal failure, respiratory depression, coma. Treatment: gastric lavage, induction of vomiting and/or administration of activated carbon (60–100 g for adults, 1–2 g/kg for children) and/or administration of osmotic laxatives, symptomatic and supportive therapy. No specific antidote has been found. Forced diuresis, urine alkalization or hemodialysis are not effective due to high protein binding.

Interactions with other drugs

Increases the toxicity of hydantoin, indirect anticoagulants, sulfonamides, methotrexate (blocks tubular secretion). Reduces the natriuretic and diuretic effect of furosemide, hypotension caused by beta-blockers. Reduces the excretion of lithium salts and increases its concentration in plasma. Antacids containing magnesium and aluminum and sucralfate may decrease the absorption of naproxen.

Precautions for use

With long-term use, it is necessary to monitor liver and kidney function and the composition of peripheral blood. If it is necessary to determine 17-ketosteroids or 5-hydroxyindolylacetic acid, treatment should be suspended 48 hours before the test.

Storage conditions

In a place protected from light. Keep out of the reach of children.

Best before date

24 months

ATX classification:

M Musculoskeletal system

M01 Anti-inflammatory and antirheumatic drugs

M01A Non-steroidal anti-inflammatory drugs

M01AE Propionic acid derivatives

M01AE02 Naproxen

Contraindications

The instructions and description of Apranax Forte warn of the presence of contraindications. Tablets are strictly not recommended for the following conditions:

  • increased individual sensitivity to naproxen;
  • allergic reaction to acetylsalicylic acid or other substances from the group of non-steroidal anti-inflammatory drugs;
  • period of pregnancy and lactation;
  • the presence of peptic ulcers of the duodenum and stomach (especially in the acute stage);
  • children's age up to 1 year.

Side effects

In most cases, the medicine is well tolerated by patients, but some side effects may develop.

In the list of possible side effects, reactions from the gastrointestinal tract are the most common. Patients note:

  • unpleasant sensation in the stomach;
  • feeling of overcrowding;
  • frequent attacks of nausea;
  • vomiting;
  • stomatitis;
  • diarrhea;
  • heartburn;
  • constipation

In this case, peptic ulcers, perforation and bleeding (gastric, intestinal) may occur. During the diagnosis, an increase in the activity of liver transaminases, jaundice, pancreatitis, colitis, melena, and hematemesis is detected.

Less commonly referred to are symptoms from the central nervous system and sensory organs. Among them:

  • dizziness;
  • headache;
  • sleep disorders;
  • depressive states;
  • decreased attention;
  • disturbance of thought processes;
  • tinnitus;
  • decreased hearing quality;
  • visual impairment;
  • vertigo develops extremely rarely;
  • muscle weakness.

The instructions for use of Apranax Forte indicate the following possible side effects from the circulatory system:

  • granulocytopenia;
  • thrombocytopenia;
  • hemolytic and aplastic anemia;
  • vasculitis

In rare cases, disruption of the reproductive system and urinary organs is observed. Among them:

  • hematuria;
  • glomerular nephritis;
  • renal failure;
  • hyperkalemia;
  • nephrotic syndrome;
  • interstitial syndrome.

Patients who are intolerant to naproxen or certain NSAIDs may experience allergic reactions. They are accompanied by:

  • Stevens-Johnson syndrome;
  • hives;
  • erythema multiforme;
  • epidermal necrolysis;
  • photodermatitis (sensitivity to light).

If one or more symptoms appear in the instructions for use of Apranax Forte, stop taking the tablets and seek medical advice.

Similar drugs:

  • Spasmalgon Tablets
  • ARTRADOL (Artradol) Lyophilisate for the preparation of solution for injection
  • Dicloberl N 75 (Dicloberl N 75) Solution for injection
  • Next Oral tablets
  • Nalbuphine Solution for injection
  • Panoxen Oral tablets
  • Katadolon Capsule
  • Meloxicam Solution for intramuscular administration
  • Optalgin Oral tablets
  • Butadion Oral tablets

** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use Apranax, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.

Are you interested in the drug Apranax? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Apranax is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!

If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.

Interaction

According to the instructions and description of Apranax Forte, tablets are often used as part of complex therapy. It is extremely important to consider the possibility of combining this medicine with other drugs used.

Taking NSAIDs can significantly reduce the effectiveness of the following drugs:

  • beta-blockers (including the substance propranolol);
  • "Furosemide".

At the same time, suppression of the renal clearance of lithium and a slowdown in the excretion of methotrexate in the urine are observed. Co-administration with probenecid causes an increase in the concentration of the drug in the blood and an increase in the half-life.

Rating
( 1 rating, average 5 out of 5 )
Did you like the article? Share with friends:
For any suggestions regarding the site: [email protected]
Для любых предложений по сайту: [email protected]